Abstract:BackgroundPancreatic Ductal Adenocarcinoma (PDAC) is a devastating disease hallmarked by limited patient survival. Resistance to chemotherapy, a major cause of treatment failure in PDAC patients, is often attributed to Cancer Stem Cells (CSCs). Pancreatic CSCs are a small subset of quiescent cells within a tumor represented by surface markers like CD133. These cells are responsible not only for tumor recurrence, but also poor prognosis based on their “stem-like” characteristics. At present, conventional therapy is directed towards rapidly dividing PDAC cells and thus fails to target the CSC population.MethodsMIA PaCa-2, S2-013 and AsPC-1 were treated with 12.5 nM triptolide (12 T cells) for 7 days. The surviving cells were recovered briefly in drug-free growth media and then transferred to Cancer Stem cell Media (CSM). As a control, untreated cells were also transferred to CSM media (CSM). The 12 T and CSM cells were tested for stemness properties using RNA and protein markers. Low numbers of CSM and 12 T cells were implanted subcutaneously in athymic nude mice to study their tumorigenic potential. 12 T and CSM cells were sorted for CD133 expression and assayed for their colony forming ability and sphere forming ability. Invasiveness of 12 T cells, CSM and MIA PaCa-2 were compared using Boyden chamber assays.ResultsTreated 12 T cells displayed increased expression of the surface marker CD133 and the drug transporter ABCG2 compared to untreated cells (CSM cells). Both 12 T and CSM cells formed subcutaneous tumors in mice confirming their tumor-initiating properties. When tested for invasion, 12 T cells had increased invasiveness compared to CSM cells. CD133+ cells in both CSM and 12 T showed greater colony and sphere forming ability compared to CD133− cells from each group. Consistent with these data, when injected subcutaneously in mice, CD133− cells from CSM or 12 T did not form any tumors whereas CD133+ cells from both groups showed tumor formation at a very low cell number. Despite pre-exposure to triptolide in 12 T CD133+ cells, treatment of tumors formed by these cells with Minnelide, a triptolide pro-drug, showed significant tumor regression.ConclusionOur results indicated that triptolide enhanced and enriched the “stemness” in the PDAC cell lines at a low dose of 12.5 nM, but also resulted in the regression of tumors derived from these cells.

Thalidomide Inhibits Proliferation and Epithelial-Mesenchymal Transition by Modulating CD133 Expression in Pancreatic Cancer Cells.

Thalidomide Suppresses Breast Cancer Tumor Growth by Inhibiting Tumor-Associated Macrophage Accumulation in Breast Tumor-Bearing Mice

Efficacy, Safety, and Potential Biomarkers of Thalidomide Plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Thalidomide Inhibits Leukemia Cell Invasion and Migration by Upregulation of Early Growth Response Gene 1

Research Progress of Thalidomide in Usual Non-Hematologic Malignancies

EFFECT OF THALIDOMIDE ON HEPATOCYTE CELL LINE SMMC-7721 HUMAN LIVER CANCER MODEL IN MICE

Importance Of The Interaction Between Immune Cells And Tumor Vasculature Mediated By Thalidomide In Cancer Treatment

Minnelide effectively eliminates CD133+ side population in pancreatic cancer

Effects of Thalidomide on the Proliferation and Gap Junction Intercellular Communication of Prostate Cancer PC-3 Cells

Study on in vitro effects and mechanism of Thalidomide on prostate cancer cell line PC-3

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4

Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

Effect of Thalidomide on the Proliferation of Hepatoma Cells Assessed by Osteopontin Levels in Nude Mice

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins.

Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease

Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454–3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC

Thalidomide Inhibits Angiogenesis Via Downregulation of VEGF and Angiopoietin-2 in Crohn’s Disease

Tumor Vasculature Remolding by Thalidomide Increases Delivery and Efficacy of Cisplatin

Experimental Study on Combination of Intratumor Scutellaria Barbata Injection and Thalidomide on Liver Cancer

Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7‐mediated activation of the Wnt/β‐catenin signaling pathway

How Thalidomide Works Against Cancer